Another New Year. Another new patent.
Stratedigm’s latest patent granted by the United States Patent Office is the next leap forward in microparticle detection. It gives users the ability to measure both small and large particles all within one sample. It provides an industry-leading three decades of dynamic range off the SSC and FSC channels when they are used for triggering-without the aid of fluorescence. Users can easily investigate specimens like mammalian cells including PBMC subsets while simultaneously detecting microparticles, such as platelets and lysosomes.
This revolutionary new patent helps to greatly reduce the inherent difficulties of generating false microparticle triggers. It relies on deconvolved signals coming from a single particle when traveling through the interrogation point. Subtle imperfections in the focused laser spot, which may cause triggers from a large particle being detected at a very low threshold, are drastically reduced or eliminated based on our technology.
Since 2008, when the S1000 series was first launched, Stratedigm has had a record number of new products and major enhancements. 2018 marks the 5th patent in a series of patents that cover many of our state-of-the-art designs, making it one of the most technologically advanced flow cytometers on the market.
To learn more about our future-proofed instruments and their investment protection characteristics:
- Contact info@stratedigm.com
- Visit us at stratedigm.com
- Visit our YouTube channel